These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 15380354

  • 1. Effect of a CCR5 inhibitor on viral loads in macaques dual-infected with R5 and X4 primate immunodeficiency viruses.
    Wolinsky SM, Veazey RS, Kunstman KJ, Klasse PJ, Dufour J, Marozsan AJ, Springer MS, Moore JP.
    Virology; 2004 Oct 10; 328(1):19-29. PubMed ID: 15380354
    [Abstract] [Full Text] [Related]

  • 2. Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection.
    Veazey RS, Klasse PJ, Ketas TJ, Reeves JD, Piatak M, Kunstman K, Kuhmann SE, Marx PA, Lifson JD, Dufour J, Mefford M, Pandrea I, Wolinsky SM, Doms RW, DeMartino JA, Siciliano SJ, Lyons K, Springer MS, Moore JP.
    J Exp Med; 2003 Nov 17; 198(10):1551-62. PubMed ID: 14623909
    [Abstract] [Full Text] [Related]

  • 3. A simian immunodeficiency virus V3 loop mutant that does not efficiently use CCR5 or common alternative coreceptors is moderately attenuated in vivo.
    Pöhlmann S, Münch J, Aziz S, Reeves JD, Otto C, Leslie GJ, Hofmann H, Puffer BA, Baribaud F, Marzi A, Gramberg T, Chen Z, Stolte N, Haaft PT, Heeney JL, Stahl-Hennig C, Mätz-Rensing K, Schneider T, Doms RW, Kirchhoff F.
    Virology; 2007 Apr 10; 360(2):275-85. PubMed ID: 17126374
    [Abstract] [Full Text] [Related]

  • 4. Innate differences between simian-human immunodeficiency virus (SHIV)(KU-2)-infected rhesus and pig-tailed macaques in development of neurological disease.
    Buch SJ, Villinger F, Pinson D, Hou Y, Adany I, Li Z, Dalal R, Raghavan R, Kumar A, Narayan O.
    Virology; 2002 Mar 30; 295(1):54-62. PubMed ID: 12033765
    [Abstract] [Full Text] [Related]

  • 5. V3 loop-determined coreceptor preference dictates the dynamics of CD4+-T-cell loss in simian-human immunodeficiency virus-infected macaques.
    Ho SH, Shek L, Gettie A, Blanchard J, Cheng-Mayer C.
    J Virol; 2005 Oct 30; 79(19):12296-303. PubMed ID: 16160156
    [Abstract] [Full Text] [Related]

  • 6. Viral evolution in macaques coinfected with CCR5- and CXCR4-tropic SHIVs in the presence or absence of vaccine-elicited anti-CCR5 SHIV neutralizing antibodies.
    Burke B, Derby NR, Kraft Z, Saunders CJ, Dai C, Llewellyn N, Zharkikh I, Vojtech L, Zhu T, Srivastava IK, Barnett SW, Stamatatos L.
    Virology; 2006 Nov 25; 355(2):138-51. PubMed ID: 16920175
    [Abstract] [Full Text] [Related]

  • 7. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion.
    Veazey RS, Klasse PJ, Schader SM, Hu Q, Ketas TJ, Lu M, Marx PA, Dufour J, Colonno RJ, Shattock RJ, Springer MS, Moore JP.
    Nature; 2005 Nov 03; 438(7064):99-102. PubMed ID: 16258536
    [Abstract] [Full Text] [Related]

  • 8. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
    Ambrose Z, Boltz V, Palmer S, Coffin JM, Hughes SH, Kewalramani VN.
    J Virol; 2004 Dec 03; 78(24):13553-61. PubMed ID: 15564466
    [Abstract] [Full Text] [Related]

  • 9. Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor.
    Veazey RS, Springer MS, Marx PA, Dufour J, Klasse PJ, Moore JP.
    Nat Med; 2005 Dec 03; 11(12):1293-4. PubMed ID: 16273102
    [Abstract] [Full Text] [Related]

  • 10. The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen.
    Waters L, Mandalia S, Randell P, Wildfire A, Gazzard B, Moyle G.
    Clin Infect Dis; 2008 May 15; 46(10):1617-23. PubMed ID: 18419499
    [Abstract] [Full Text] [Related]

  • 11. CD4+ CCR5+ T-cell dynamics during simian immunodeficiency virus infection of Chinese rhesus macaques.
    Monceaux V, Viollet L, Petit F, Cumont MC, Kaufmann GR, Aubertin AM, Hurtrel B, Silvestri G, Estaquier J.
    J Virol; 2007 Dec 15; 81(24):13865-75. PubMed ID: 17898067
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of CCR5-mediated infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule inhibitors of CCR5: effects of viral diversity, target cell and receptor density.
    Willey S, Peters PJ, Sullivan WM, Dorr P, Perros M, Clapham PR.
    Antiviral Res; 2005 Nov 15; 68(2):96-108. PubMed ID: 16157392
    [Abstract] [Full Text] [Related]

  • 13. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.
    Wilkin TJ, Su Z, Kuritzkes DR, Hughes M, Flexner C, Gross R, Coakley E, Greaves W, Godfrey C, Skolnik PR, Timpone J, Rodriguez B, Gulick RM.
    Clin Infect Dis; 2007 Feb 15; 44(4):591-5. PubMed ID: 17243065
    [Abstract] [Full Text] [Related]

  • 14. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
    Marozsan AJ, Kuhmann SE, Morgan T, Herrera C, Rivera-Troche E, Xu S, Baroudy BM, Strizki J, Moore JP.
    Virology; 2005 Jul 20; 338(1):182-99. PubMed ID: 15935415
    [Abstract] [Full Text] [Related]

  • 15. Suppression of multiclade R5 and X4 human immunodeficiency virus type-1 infections by a coreceptor-based anti-HIV strategy.
    Nakayama D, Misumi S, Mukai R, Tachibana K, Umeda M, Shibata H, Takamune N, Shoji S.
    J Biochem; 2005 Nov 20; 138(5):571-82. PubMed ID: 16272569
    [Abstract] [Full Text] [Related]

  • 16. Genotypic coreceptor analysis.
    Sierra S, Kaiser R, Thielen A, Lengauer T.
    Eur J Med Res; 2007 Oct 15; 12(9):453-62. PubMed ID: 17933727
    [Abstract] [Full Text] [Related]

  • 17. HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia.
    Spudich SS, Huang W, Nilsson AC, Petropoulos CJ, Liegler TJ, Whitcomb JM, Price RW.
    J Infect Dis; 2005 Mar 15; 191(6):890-8. PubMed ID: 15717264
    [Abstract] [Full Text] [Related]

  • 18. Replicative fitness of CCR5-using and CXCR4-using human immunodeficiency virus type 1 biological clones.
    Ariën KK, Gali Y, El-Abdellati A, Heyndrickx L, Janssens W, Vanham G.
    Virology; 2006 Mar 30; 347(1):65-74. PubMed ID: 16386774
    [Abstract] [Full Text] [Related]

  • 19. HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART.
    Soulié C, Marcelin AG, Ghosn J, Amellal B, Assoumou L, Lambert S, Duvivier C, Costagliola D, Katlama C, Calvez V.
    AIDS; 2007 Oct 18; 21(16):2243-5. PubMed ID: 18090053
    [Abstract] [Full Text] [Related]

  • 20. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques.
    Hazuda DJ, Young SD, Guare JP, Anthony NJ, Gomez RP, Wai JS, Vacca JP, Handt L, Motzel SL, Klein HJ, Dornadula G, Danovich RM, Witmer MV, Wilson KA, Tussey L, Schleif WA, Gabryelski LS, Jin L, Miller MD, Casimiro DR, Emini EA, Shiver JW.
    Science; 2004 Jul 23; 305(5683):528-32. PubMed ID: 15247437
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.